STOCKHOLM, Sept. 23, 2019 /PRNewswire/ -- IRLAB announced
today that Prof. Per Svenningsson, on behalf of IRLAB, will be
presenting a poster titled "A phase IIa trial studying the
safety and tolerability of IRL752 in patients with Parkinson's
disease dementia" at the 2019 International Congress of Parkinson's
Disease and Movement Disorders in Nice,
France. The presentation will be held on Monday, September
23.
The 2019 International Congress of Parkinson's Disease and
Movement Disorders is held on September
22-26 and aims to encourage sharing ideas among those
involved in the care and research of movement disorders to advance
the related clinical and scientific discipline. Congress audience
will include clinicians, researchers, healthcare professionals,
post-doctoral fellows, medical residents and medical students with
an interest in the current research and approaches for the
diagnosis and treatment of movement disorders.
Nicholas Waters, CEO at IRLAB,
commented "Prof. Svenningsson is an outstanding researcher and we
are glad to be working closely with him. It is great to get this
type of recognition in the medical community and it is a privilege
to be selected to present at the congress, which also means that
our data caught the interest of the congress committee among many
other abstract submissions."
Find the poster presentation at the congress:
Abstract number: 209
Abstract title: A phase IIa trial studying the safety and
tolerability of IRL752 in patients with Parkinson's disease
dementia
Poster session topic: Clinical Trials, Pharmacology and
Treatment
Presentation Date: Monday, September
23
Presentation time: 13:45 – 15:15
For further information
Nicholas Waters
CEO
Phone: +46-730-75-77-01
E-mail: nicholas.waters@irlab.se
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irlab-therapeutics-ab/r/irlab-presents-at-the-2019-international-congress-of-parkinson-s-disease-and-movement-disorders,c2912593
The following files are available for download:
https://mb.cision.com/Main/15440/2912593/1109966.pdf
|
Release
|